Physician profile
Bobby Muthalaly
NPI 1457375586
$12,050.17
in general payments reported to CMS, 2019-2025
31 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $154 · 2021: $2,920 · 2022: $1,765 · 2023: $3,888 · 2024: $1,369 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,607 · Consulting Fee: $2,700 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,607.09 |
| Consulting Fee | $2,700.00 |
| Education | $132.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $6,659.68 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $874.20 | 2019-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $549.15 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $504.14 | 2020-2025 | Tavneos, Krystexxa |
| Calliditas Therapeutics US INC. | $414.56 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $392.98 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $348.17 | 2019-2025 | |
| Vifor Pharma, INC. | $292.86 | 2019-2025 | Veltassa |
| Alexion Pharmaceuticals, INC. | $287.17 | 2019-2025 | Ultomiris |
| Opko Pharmaceuticals, LLC | $206.14 | 2019-2024 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.89 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $169.57 | 2021-2024 | Velphoro, Korsuva |
| Daiichi Sankyo INC. | $167.67 | 2020-2023 | Injectafer |
| Mallinckrodt Enterprises LLC | $127.42 | 2019 | |
| Ardelyx, INC. | $122.06 | 2023-2025 | Ibsrela |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $102.55 | 2021-2023 | Krystexxa |
| Akebia Therapeutics INC | $99.68 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $87.05 | 2023-2025 | Prevymis, Dificid, Zerbaxa |
| Mallinckrodt Hospital Products INC. | $69.21 | 2022-2025 | Terlivaz |
| Baxter Healthcare | $65.07 | 2019 | |
| Novo Nordisk INC | $52.50 | 2025 | Wegovy, Ozempic, Rybelsus |
| Apellis Pharmaceuticals, INC. | $49.90 | 2025 | Empaveli |
| Genentech USA, INC. | $41.53 | 2019 | |
| Glaxosmithkline, LLC. | $39.04 | 2021-2022 | |
| Cormedix INC. | $31.05 | 2024 | Defencath |
| Veloxis Pharmaceuticals, INC. | $29.75 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.50 | 2019 | |
| Aurinia Pharma U.S., INC. | $24.08 | 2023 | Lupkynis |
| Pharmacosmos Therapeutics INC. | $17.27 | 2023 | Monoferric |
| Janssen Pharmaceuticals, INC | $15.79 | 2019 | |
| Ani Pharmaceuticals, INC. | $15.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Muthalaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.